NDA 021845 · Viatris
Revatio
Sildenafil Citrate · Oral
Priority reviewLast checked: Nov 19, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jun 3, 2005
Approved uses
5
Original approval plus efficacy supplements
Registered trials
439
87 Phase 3, 20 recruiting
FAERS reports
55,254
38,247 serious, 10,436 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 18, 2024.
Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14) ] . Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14) ] . Adults REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening. ( 1 ) Pediatric Patients (1 to 17 years old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standard exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise ( 1 , 14 )
Mechanism: Sildenafil is an inhibitor of cGMP specific PDE-5 in the smooth muscle of the pulmonary vasculature, where PDE-5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with PAH, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation. Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, greater than 80-fold for...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 31, 2023 Supplement 25 · Efficacy LetterLabelReview
- Jan 31, 2014 Supplement 12 · Efficacy LabelLetter
- Aug 30, 2012 Supplement 8 · Efficacy LabelLetter
- May 7, 2009 Supplement 6 · Efficacy LetterLabel
- Jun 3, 2005 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Other Important Information from FDALetterReview
1 products under this application
- REVATIO · SILDENAFIL CITRATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sildenafil" as an intervention, any sponsor and status, largest first.
- Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across NationsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00547287 · 2,760 participants · Start Nov 2002
Drug: tadalafil; sildenafil · For: Impotence
Sites: São Paulo, Brazil
- Cost-effective Treatment of Unexplained InfertilityPivotal-lookingCompleted
Batterjee Medical CollegeAcademic, hospital or other
NCT06178523 · 900 participants · Start Jan 1, 2024 · Primary completion Dec 31, 2024
Drug: Clomiphene Citrate.; Sildenafil Citrate · For: Unexplained Infertility
Sites: Jeddah, Saudi Arabia
- A Study to Evaluate Self-esteem and Relationships in Males With Erectile DysfuntionPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00648596 · 780 participants · Start May 2003
Drug: sildenafil; placebo · For: Erectile Dysfunction
Sites: Oulu, Finland; Tampere, Finland; Turku, Finland · 66 sites in all
- A Study in Patients With Erectile DysfunctionPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01122264 · 770 participants · Start May 2010 · Primary completion Jun 2011
Drug: Tadalafil; Sildenafil Citrate · For: Erectile Dysfunction
Sites: Carpentras, France; Chambéry, France; La Bouëxière, France · 45 sites in all
- Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo TransferPivotal-lookingCompleted
Wael Elbanna ClinicAcademic, hospital or other
NCT03945812 · 665 participants · Start Jun 1, 2019 · Primary completion Mar 31, 2022
Drug: Granulocyte Colony Stimulating Factor · For: Infertility; Frozen Embryo Transfer (FET)
Sites: Maadi, Egypt
- Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00457457 · 609 participants · Start May 2007 · Primary completion Apr 2008
Drug: Tamsulosin; UK-369,003 · For: Prostatic Hyperplasia
Sites: Herston, Australia; Adelaide, Australia; Brussels, Belgium · 46 sites in all
- Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.Pivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00249730 · 510 participants · Start Oct 2005
Drug: Sildenafil · For: Impotence
Sites: Kitchener, Canada; Sarnia, Canada; Toronto, Canada · 39 sites in all
- Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder PatientsPivotal-lookingRecruiting
Mansoura UniversityAcademic, hospital or other
NCT07391579 · 500 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 2026
Drug: Tadalafil 5 mg & Sildenafil 100mg; Sildenafil 100mg & placebo · For: Erectile Dysfunctions
Sites: Al Mansurah, Egypt; Alexandria, Egypt; Aswān, Egypt · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea8,445
- headache5,765
- death5,676
- diarrhoea4,437
- nausea3,833
- fatigue3,640
- dizziness3,413
- cough3,389
- pneumonia3,057
- malaise2,716
- fluid retention2,314
- hypotension2,215
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 60 |
| 2005 | 120 |
| 2006 | 309 |
| 2007 | 259 |
| 2008 | 493 |
| 2009 | 696 |
| 2010 | 1,588 |
| 2011 | 2,325 |
| 2012 | 2,533 |
| 2013 | 2,825 |
| 2014 | 5,734 |
| 2015 | 4,431 |
| 2016 | 3,367 |
| 2017 | 4,035 |
| 2018 | 3,584 |
| 2019 | 3,653 |
| 2020 | 3,427 |
| 2021 | 2,839 |
| 2022 | 2,721 |
| 2023 | 2,774 |
| 2024 | 2,725 |
| 2025 | 2,704 |
| 2026 | 2,052 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Revatio (Sildenafil Citrate)
2024 spending
$7.2M
Beneficiaries
100
684 claims
Per beneficiary
$72,205
$58.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,426,297 |
| 2021 | $8,648,798 |
| 2022 | $8,211,892 |
| 2023 | $7,734,036 |
| 2024 | $7,220,470 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intrapartum Sildenafil to Improve Perinatal Outcomes: A Randomized Clinical Trial.
Kumar S, Tarnow-Mordi W, Mol BW, et al. · JAMA 2025 · Multicenter Study, Pragmatic Clinical Trial
- Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial.
Kallimath A, Deshpande S, Singh P, et al. · BMC Pediatr 2024 · Randomized Controlled Trial, Comparative Study
- Sildenafil improves clinical signs and radiographic features in dogs with congenital idiopathic megaoesophagus: a randomised controlled trial.
Quintavalla F, Menozzi A, Pozzoli C, et al. · Vet Rec 2017 · Randomized Controlled Trial
- Sildenafil for pulmonary hypertension.
Kanthapillai P, Lasserson T, Walters E · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Sildenafil affects olfactory function.
Gudziol V, Mück-Weymann M, Seizinger O, et al. · J Urol 2007 · Randomized Controlled Trial
- Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.
Hoeper MM, Ewert R, Jansa P, et al. · Circulation 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.